Skip to main content

Lakewood-Amedex Biotherapeutics Inc.

corporate_fare Company Profile

Lakewood-Amedex Biotherapeutics Inc.

LABT·NASDAQ·Life Sciences·CIK 0002079272

Lakewood-Amedex Biotherapeutics Inc. is a clinical-stage biotechnology company focused on developing antimicrobial products in the United States. The company's primary offerings include products from its Bisphosphocin class, which are a novel type of antimicrobial agents designed to combat infections by disrupting the membranes of microbes. Additionally, Lakewood-Amedex Biotherapeutics Inc. is developing Nu-3, a topical antimicrobial specifically intended for treating infected diabetic foot ulcers. The company, originally incorporated in 2006, was formerly known as Lakewood-Amedex Inc. and adopted its current name, Lakewood-Amedex Biotherapeutics, Inc., in June 2025. Its headquarters are located in University Park, Florida.

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) is a publicly traded company in the Life Sciences sector. Wiseek monitors LABT SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Lakewood-Amedex Expands Global IP Portfolio for Lead Drug Nu-3 with New Patents in Australia, New Zealand
  • Lakewood-Amedex Finalizes Highly Dilutive Series C Offering and Conversions, Doubling Share Count Amid Going Concern Warning
  • Lakewood-Amedex Reports Wider Q1 Losses, ($0.20) EPS and Negative Revenue
  • Going Concern Warning Persists Amidst Highly Dilutive Financing and Nasdaq Listing
  • Positive Data for Lead Candidate Nu-3 Propels Lakewood-Amedex Towards Phase 2 Trial
Browse all tickers starting with L →
$0.7305 -0.04% today
52-week range · as of 2026-05-26 $0.66 – $9.82
Market cap
$5.37M
Volume
301.5K (0.1× avg)
3-mo avg 3.2M
Live data · 2026-06-14 05:13 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LABT - Latest Insights

LABT
May 27, 2026, 8:02 AM EDT
Source: PR Newswire
Importance Score:
7
Lakewood-Amedex Expands Global IP Portfolio for Lead Drug Nu-3 with New Patents in Australia, New Zealand
Price at Filing: $0.698
Real-time Price: $0.7305 info
Change: +$0.0325 (+5%) info
Market Cap: $5.368M info
Sentiment: Positive
View Wiseek Article
LABT
May 26, 2026, 4:06 PM EDT
Filing Type: 424B3
Importance Score:
9
Lakewood-Amedex Finalizes Highly Dilutive Series C Offering and Conversions, Doubling Share Count Amid Going Concern Warning
Price at Filing: $0.727
Real-time Price: $0.7305 info
Change: +$0.0035 (+0.48%) info
Market Cap: $5.368M info
Sentiment: Negative
View Wiseek Article
LABT
May 22, 2026, 5:01 PM EDT
Source: Wiseek News
Importance Score:
7
Lakewood-Amedex Reports Wider Q1 Losses, ($0.20) EPS and Negative Revenue
Price at Filing: $0.7083
Real-time Price: $0.7305 info
Change: +$0.0222 (+3%) info
Market Cap: $5.368M info
Sentiment: Negative
View Wiseek Article
LABT
May 22, 2026, 4:55 PM EDT
Filing Type: 10-Q
Importance Score:
9
Going Concern Warning Persists Amidst Highly Dilutive Financing and Nasdaq Listing
Price at Filing: $0.7022
Real-time Price: $0.7305 info
Change: +$0.0283 (+4%) info
Market Cap: $5.368M info
Sentiment: Negative
View Wiseek Article
LABT
May 18, 2026, 9:20 AM EDT
Source: Reuters
Importance Score:
8
Positive Data for Lead Candidate Nu-3 Propels Lakewood-Amedex Towards Phase 2 Trial
Price at Filing: $1.26
Real-time Price: $0.7305 info
Change: -$0.5297 (-42%) info
Market Cap: $5.368M info
Sentiment: Positive
View Wiseek Article
LABT
May 14, 2026, 4:18 PM EDT
Filing Type: 424B4
Importance Score:
9
Major Investors & Financial Advisor Resell 9.6M Shares, Company Receives No Proceeds Amidst 'Going Concern' Warning
Price at Filing: $1.98
Real-time Price: $0.7305 info
Change: -$1.25 (-63%) info
Market Cap: $5.368M info
Sentiment: Negative
View Wiseek Article
LABT
May 12, 2026, 8:02 AM EDT
Source: PR Newswire
Importance Score:
7
Lakewood-Amedex Secures CRO for Nu-3 Phase 2 Trial, Advancing Lead Candidate
Price at Filing: $3.16
Real-time Price: $0.7305 info
Change: -$2.43 (-77%) info
Market Cap: $5.368M info
Sentiment: Positive
View Wiseek Article
LABT
May 01, 2026, 4:05 PM EDT
Filing Type: S-1
Importance Score:
8
Selling Stockholders Register Over 9.6M Shares for Resale, Posing Significant Dilution Risk Amidst Going Concern Warning
Price at Filing: $3.27
Real-time Price: $0.7305 info
Change: -$2.54 (-78%) info
Market Cap: $5.368M info
Sentiment: Negative
View Wiseek Article
LABT
May 01, 2026, 9:33 AM EDT
Source: Reuters
Importance Score:
8
Lead Candidate NU-3 Shows Strong Antimicrobial Resistance Data for Diabetic Foot Ulcers
Price at Filing: $4.22
Real-time Price: $0.7305 info
Change: -$3.48 (-83%) info
Market Cap: $5.368M info
Sentiment: Positive
View Wiseek Article
LABT
Apr 28, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
7
Lakewood-Amedex Appoints Biotech Veteran Dr. Joseph Tucker to Board, Bolstering Capital Markets Expertise
Price at Filing: $3.95
Real-time Price: $0.7305 info
Change: -$3.22 (-82%) info
Market Cap: $5.368M info
Sentiment: Positive
View Wiseek Article